Rigel Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤Q3 total revenue $80.9 million, including $72.3 million product sales
- ➤Q3 net income $13.2 million, down from $27.9 million year-over-year
- ➤VEPPANU generated $6.6 million in initial Q3 net product sales
- ➤2026 revenue guidance raised to approximately $290-$295 million, excluding VEPPANU
- ➤R289 Phase 1b dose selection expected by end of 2026; ASH data due December
Expert Statements
Raul Rodriguez, President and CEO of Rigel Pharmaceuticals
“VEPPANU's launch marks an exciting and transformational milestone for Rigel and we are very pleased with the initial uptake. In the first six weeks of launch we shipped VEPPANU to more than 100 patients and clinics and have already seen many refills,”
Raul Rodriguez, President and CEO of Rigel Pharmaceuticals
“Our priorities are to build on the VEPPANU launch and advance R289 in lower-risk MDS, with updated Phase 1b data to be presented at ASH in December. We believe VEPPANU and R289 have significant commercial potential to further transform Rigel and drive long-term shareholder value.”
Rigel Reports Third Quarter 2026 Financial Results PR Newswire
* Third quarter 2026 total revenues of $80.9 million, including net product sales of $72.3 million and contract revenues from collaborations of $8.6 million, and net income of $13.2 million * VEPPANU(™) (vepdegestrant) became commercially available in mid-August and generated $6.6 million in initial net product sales for the third quarter * The Phase 1b study of R289, Rigel's dual IRAK1/4 inhibitor, in patients with lower-risk MDS is ongoing and Rigel expects to select the recommended Phase 2 dose by the end of 2026 * Oral presentation at the ASH Annual Meeting in December will feature updated data from the ongoing Phase 1b study of R289 in patients with lower-risk MDS * Updated 2026 Outlook: Total revenues of approximately $290 to $295 million, which includes net product sales, excluding VEPPANU, of $255 to $260 million and contract revenues from collaborations of approximately $35 million * Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 5, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the third quarter ended September 30, 2026, including sales of TAVALISSE(®) (fostamatinib disodium hexahydrate), REZLIDHIA(®) (olutasidenib), GAVRETO(®) (pralsetinib) and VEPPANU(™) (vepdegestrant).
Get started
Create a free account to read the full story.